SE0003766D0 - Novel formulation - Google Patents

Novel formulation

Info

Publication number
SE0003766D0
SE0003766D0 SE0003766A SE0003766A SE0003766D0 SE 0003766 D0 SE0003766 D0 SE 0003766D0 SE 0003766 A SE0003766 A SE 0003766A SE 0003766 A SE0003766 A SE 0003766A SE 0003766 D0 SE0003766 D0 SE 0003766D0
Authority
SE
Sweden
Prior art keywords
inhibitor
hmg
bile acid
ibat
ibat inhibitor
Prior art date
Application number
SE0003766A
Other languages
English (en)
Inventor
Bertil Abrahamsson
Ann-Margret Lindqvist
Ingemar Starke
Anna-Lena Ungell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0003766A priority Critical patent/SE0003766D0/sv
Publication of SE0003766D0 publication Critical patent/SE0003766D0/sv
Priority to IL15010401A priority patent/IL150104A0/xx
Priority to KR1020027007742A priority patent/KR20020062970A/ko
Priority to AU2001294002A priority patent/AU2001294002A1/en
Priority to PCT/GB2001/004525 priority patent/WO2002032428A1/en
Priority to EP01974487A priority patent/EP1351692A1/en
Priority to CA002425831A priority patent/CA2425831A1/en
Priority to HU0301087A priority patent/HUP0301087A3/hu
Priority to PL36093701A priority patent/PL360937A1/xx
Priority to BR0107333-8A priority patent/BR0107333A/pt
Priority to SK473-2003A priority patent/SK4732003A3/sk
Priority to NZ525371A priority patent/NZ525371A/en
Priority to CN01804901A priority patent/CN1400902A/zh
Priority to MXPA03003417A priority patent/MXPA03003417A/es
Priority to JP2002535666A priority patent/JP2004511521A/ja
Priority to US10/399,336 priority patent/US20050101611A1/en
Priority to ZA200204771A priority patent/ZA200204771B/en
Priority to NO20022894A priority patent/NO20022894L/no
Priority to IS6784A priority patent/IS6784A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
SE0003766A 2000-10-18 2000-10-18 Novel formulation SE0003766D0 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE0003766A SE0003766D0 (sv) 2000-10-18 2000-10-18 Novel formulation
US10/399,336 US20050101611A1 (en) 2000-10-18 2001-10-12 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
PL36093701A PL360937A1 (en) 2000-10-18 2001-10-12 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
SK473-2003A SK4732003A3 (en) 2000-10-18 2001-10-12 Oral formulation comprising an inhibitor compound of the ileal bile transport and an HMG Co-A reductase inhibitor
AU2001294002A AU2001294002A1 (en) 2000-10-18 2001-10-12 Oral formulation comprising an inhibitor compound of the ileal bile transport and an HMG Co-A reductase inhibitor
PCT/GB2001/004525 WO2002032428A1 (en) 2000-10-18 2001-10-12 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
EP01974487A EP1351692A1 (en) 2000-10-18 2001-10-12 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
CA002425831A CA2425831A1 (en) 2000-10-18 2001-10-12 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
HU0301087A HUP0301087A3 (en) 2000-10-18 2001-10-12 Oral pharmaceutical composition comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
IL15010401A IL150104A0 (en) 2000-10-18 2001-10-12 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
BR0107333-8A BR0107333A (pt) 2000-10-18 2001-10-12 Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo sofrendo de, ou susceptìvel a, hipercolesterolemia e diarréia, e, uso de um aglutinante de ácidos biliares
KR1020027007742A KR20020062970A (ko) 2000-10-18 2001-10-12 회장 담즙 수송 억제제 화합물 및 ｈｍｇ ｃｏ-ａ리덕타제 억제제를 함유하는 경구 제제
NZ525371A NZ525371A (en) 2000-10-18 2001-10-12 Oral formulation comprising an inhibitor compound of the ileal bile transport and an HMG Co-A reductase inhibitor
CN01804901A CN1400902A (zh) 2000-10-18 2001-10-12 含有回肠胆汁转运抑制剂化合物和HMGCo－A还原酶抑制剂的口服制剂
MXPA03003417A MXPA03003417A (es) 2000-10-18 2001-10-12 Formulacion oral que comprende un compuesto inhibidor del transporte biliar ileal y un inhibidor de reductasa hmgco-a.
JP2002535666A JP2004511521A (ja) 2000-10-18 2001-10-12 回腸胆汁輸送の阻害化合物とＨＭＧ−ＣｏＡレダクターゼ阻害剤を含んでなる経口製剤
ZA200204771A ZA200204771B (en) 2000-10-18 2002-06-13 Oral formulation comprising an inhibitor compound of the ileal bile transport and an HMG Co-A reductase inhibitor.
NO20022894A NO20022894L (no) 2000-10-18 2002-06-17 Oral formulering omfattende en inhibitorforbindelse av ileum- galle transport og en HMG CO-A reduktase inhibitor
IS6784A IS6784A (is) 2000-10-18 2003-04-14 Blanda til inntöku um munn sem felur í sér efnasamband sem hamlar flutningi galls í dausgörn og HMGCo-A redúktasahemil

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0003766A SE0003766D0 (sv) 2000-10-18 2000-10-18 Novel formulation

Publications (1)

Publication Number Publication Date
SE0003766D0 true SE0003766D0 (sv) 2000-10-18

Family

ID=20281462

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0003766A SE0003766D0 (sv) 2000-10-18 2000-10-18 Novel formulation

Country Status (19)

Country Link
US (1) US20050101611A1 (sv)
EP (1) EP1351692A1 (sv)
JP (1) JP2004511521A (sv)
KR (1) KR20020062970A (sv)
CN (1) CN1400902A (sv)
AU (1) AU2001294002A1 (sv)
BR (1) BR0107333A (sv)
CA (1) CA2425831A1 (sv)
HU (1) HUP0301087A3 (sv)
IL (1) IL150104A0 (sv)
IS (1) IS6784A (sv)
MX (1) MXPA03003417A (sv)
NO (1) NO20022894L (sv)
NZ (1) NZ525371A (sv)
PL (1) PL360937A1 (sv)
SE (1) SE0003766D0 (sv)
SK (1) SK4732003A3 (sv)
WO (1) WO2002032428A1 (sv)
ZA (1) ZA200204771B (sv)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
ATE349214T1 (de) 2001-09-08 2007-01-15 Astrazeneca Ab Benzothiazepin und benzothiadiazepin derivative mit hemmender wirkung auf den säuretransport in den gallengängen zur behandlung von hyperlipidaemia
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
ATE386013T1 (de) 2002-06-20 2008-03-15 Astrazeneca Ab Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
US20130225511A1 (en) 2010-11-08 2013-08-29 Per-Göran Gillberg Ibat inhibitors for the treatment of liver diseases
AU2011326872C1 (en) * 2010-11-08 2015-02-19 Albireo Ab A pharmaceutical combination comprising an IBAT inhibitor and a bile acid binder
WO2013063512A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN105362244A (zh) * 2015-11-26 2016-03-02 青岛海之源智能技术有限公司 考来烯胺缓释片及制备方法
CN108601745B (zh) 2016-02-09 2021-12-07 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JOP20200297A1 (ar) 2018-06-20 2020-11-22 Albireo Ab تعديلات بلورية للأوديفيكسيبات
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CN113453753A (zh) 2019-02-06 2021-09-28 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP2022519370A (ja) 2019-02-06 2022-03-23 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
PE20230234A1 (es) 2019-12-04 2023-02-07 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134218A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
WO2022117778A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600578A (en) * 1984-05-11 1986-07-15 Bristol-Myers Company Method of inhibiting diarrhea
US5362732A (en) * 1989-12-20 1994-11-08 University Of North Carolina At Chapel Hill Boronated compounds
JPH04193836A (ja) * 1990-11-26 1992-07-13 Banyu Pharmaceut Co Ltd 抗高脂血症剤
FI108451B (sv) * 1991-12-20 2002-01-31 Hoechst Ag F÷rfarande f÷r framstõllning av polymera och oligomera gallsyror
IL108633A (en) * 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
GB9704208D0 (en) * 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
CA2283575A1 (en) * 1997-03-11 1998-09-17 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
GB9800428D0 (en) * 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
NZ525371A (en) 2004-11-26
ZA200204771B (en) 2003-09-15
HUP0301087A2 (hu) 2003-11-28
IL150104A0 (en) 2002-12-01
CN1400902A (zh) 2003-03-05
PL360937A1 (en) 2004-09-20
CA2425831A1 (en) 2002-04-25
EP1351692A1 (en) 2003-10-15
AU2001294002A1 (en) 2002-04-29
BR0107333A (pt) 2002-08-27
US20050101611A1 (en) 2005-05-12
JP2004511521A (ja) 2004-04-15
MXPA03003417A (es) 2003-08-07
KR20020062970A (ko) 2002-07-31
IS6784A (is) 2003-04-14
HUP0301087A3 (en) 2005-06-28
NO20022894L (no) 2002-08-15
SK4732003A3 (en) 2003-10-07
WO2002032428A1 (en) 2002-04-25
NO20022894D0 (no) 2002-06-17

Similar Documents

Publication Publication Date Title
SE0003766D0 (sv) Novel formulation
SE9901387D0 (sv) New pharmaceutical foromaulations
AU1562995A (en) Method for increasing bioavailability of oral pharmaceutical compositions
MY142441A (en) Azole derivatives as inhibitors of lipases and phospholipases
ATE240334T1 (de) Pyrrolobenzodiazepine
WO2002018327A3 (en) Guanidinobenzamides as mc4-r agonists
RS52110B (en) DIPEPTIDIL PEPTIDASE INHIBITORS FOR TREATMENT OF DIABETES
AU2003282983A1 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
ATE302746T1 (de) Amorphe salpetersäureester und deren pharmazeutische zusammensetzungen
PT1165065E (pt) Comprimidos para degluticao com elevada concentracao de n-acetilcisteina
AU2003292006A1 (en) 3,5,3'-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
PL1498119T3 (pl) Zastosowanie sprzężonych dienów kwasu linolowego do leczenia przeziębienia
UA90700C2 (ru) Оральная композиция немедленного выделения на основе слабоводорастворимого действующего вещества
DE60231997D1 (de) Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung
AU3903701A (en) Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase
AU1580395A (en) Microgranules of 5-nitro imidazole derivatives
GB0206200D0 (en) Pharmaceutical compositions
AU2579500A (en) Improvements to the use of magnetic microfields for burning fuel
NZ512047A (en) Synthesis of ester linked long chain alkyl moieties
MY132962A (en) Inotropic agents with negative chronotropic and vasodilatory effects